Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | TLR4 | O00206 | 1/20 | 0.32 |
| ▸ | TLR2 | O60603 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4807633 | 1.00 | MAOA (0.34) | MAOAMAOBTLR4TLR2IDO1 | |
| SCHEMBL4800552 | 0.82 | CTSL (0.45) | MAOAMAOBTLR4TLR2CTSL | |
| SCHEMBL4800555 | 0.82 | CTSL (0.45) | MAOAMAOBTLR4TLR2CTSL | |
| SCHEMBL4809366 | 0.79 | IDO1 (0.38) | MAOBIDO1 | |
| SCHEMBL4803004 | 0.79 | IDO1 (0.38) | MAOBIDO1 | |
| SCHEMBL4802994 | 0.79 | IDO1 (0.38) | MAOBIDO1 | |
| SCHEMBL4806232 | 0.76 | CTSL (0.30) | MAOAMAOBTLR4TLR2CTSL | |
| SCHEMBL4806217 | 0.76 | CTSL (0.30) | MAOAMAOBTLR4TLR2CTSL | |
| SCHEMBL4800718 | 0.67 | SLC1A2 (0.39) | MAOBIDO1 | |
| SCHEMBL4798572 | 0.66 | CTSL (0.33) | MAOAMAOBTLR4TLR2CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446125-B2 | Derivatives of nitroproline compounds, processes of manufacture and uses in the treatment of integrin mediated disorders | UNIVERSIDAD DEL PAIS VASCO (ES) | 2008-11-04 | — | — | US | disclosed |
| US-20060211630-A1 | Novel synthetic compounds, processes of manufacture and uses in the treatment of integrin-mediated disorders | UNIVERSIDAD DEL PAIS VASCO (ES) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211630-A1 | Novel synthetic compounds, processes of manufacture and uses in the treatment of integrin-mediated disorders | ITGB5, ITGA5, ITGAV | MAOA 3714/4885MAOB 3097/4885TLR4 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.